WORLD: New concerns about the efficacy of the Sinovac vaccine have emerged after confirmation that more than 350 doctors and healthcare workers in Indonesia have contracted COVID-19 and have been hospitalized, despite having previously been inoculated with the vaccine.
The COVID-19 Delta variant is behind recent outbreaks across Indonesia, raising serious concerns for health authorities. Photo: AFP.
The more transmissible Delta variant of COVID-19 is believed to be responsible for the latest outbreak in Kudus, which has left the healthcare system stretched with bed occupancy rates in local hospitals exceeding 90%.
“The data shows they have the Delta variant [in Kudus] It is therefore not surprising that the breakthrough infection is higher than before, because as we know the majority of healthcare workers in Indonesia have received Sinovac, and we still do not yet know how much it is effective in the real world against the Delta variant, ”said Dicky Budiman, epidemiologist at Griffith University in Australia.
As was the case in many countries, frontline healthcare workers in Indonesia were among the first to be vaccinated, and almost all of them received the Chinese-made Sinovac. The World Health Organization (WHO) approved emergency use of the Sinovac vaccine this month.
When approached by Reuters to comment on the vaccine’s effectiveness against the new variant, neither the Indonesian health ministry nor CoronaVac, the Chinese company that produces Sinovac, were available.
Indonesia, the world’s fourth most populous country, has recorded 1.9 million cases of COVID-19 infection since the pandemic began last year. Of this number, 1.76 min were confirmed as recovered. To date, 53,476 deaths have been recorded.